AstraZeneca axes another 7,300 jobs worldwide

 


The pharmaceuticals industry was dealt a fresh blow today after AstraZeneca announced a further 7,300 job cuts amid warnings that its profits will slide this year.

The UK's second biggest drugs maker, which has 61,000 staff globally, said it was too early to say how many of its 8,000 staff in the UK would be affected.

It has already cut 21,600 staff globally since 2007 as part of two previous restructuring initiatives, including the closure of a site at Charnwood near Loughborough at the end of last year.

Unions have said that 250 to 300 of the latest cuts will be in research and development at the firm's site in Alderley Park, Cheshire, while there would be further back office cuts at other UK sites.

Its other sites in the UK are at Macclesfield, Cambridge, Luton, Avlon near Bristol, Paddington in London, and Brixham in Devon.

The latest round of cuts comes a year after rival Pfizer said it would pull the plug on its plant in Sandwich, Kent, which employed 2,400 staff.

The pharmaceuticals industry has come under pressure because its major players have struggled to invent new blockbuster drugs as patents on existing best sellers expire, leaving them open to cheap competition. Governments are also looking to reduce the prices they charge.

The industry's problems are a particular worry for the UK, which is a world leader in the field. Some 67,000 people work in the industry in the UK, of which more than a third are in research and development.

The Government, which hopes manufacturers will spearhead the recovery, has introduced lower taxes on patents to try to encourage companies to carry out more research in the UK.

Allan Black, GMB national officer for pharmaceuticals, said: "These cutting-edge research and development jobs are both well-paid and essential for a thriving UK economy.

"As a nation we do need to find a viable way to continue to make breakthroughs in bringing to safe use much-needed new medicines."

The jobs blow came as the Cheshire-based company announced a 2 per cent fall in revenues to 33.3 billion US dollars (£21.1 billion) in 2011, while profits fell 4 per cent to 13.2 billion US dollars (£8.4 billion).

Shares were down 3 per cent as the company warned that revenues for 2012 are likely to be down by more than 10 per cent while its margins will also be squeezed, leading to lower profits.

The Anglo-Swedish company has suffered a number of setbacks in its efforts to secure approval for new blockbuster drugs.

It recently warned that profits would be at the low end of analysts' expectations after ovarian cancer drug olaparib was held back for further development when tests proved it was unlikely to prove effective.

The results of tests on drugs for patients with major depressive disorders were disappointing so far, and the US Food and Drug Administration recently declined approval of a new diabetes drug dapagliflozin.

Analysts have also been underwhelmed by sales of its new blood thinning drug Brilinta.

In addition, its anti-psychotic drug Seroquel will lose exclusivity in the United States and many European countries this year.

Astra warned that the coming years would be "challenging for the industry and for the company".

Chief executive David Brennan said: "Disciplined execution of our strategy has delivered a good performance in 2011 in the face of intensified pricing pressure and generic competition.

"While the further expected losses of market exclusivity make for a challenging 2012 outlook, we remain committed to a long-term, focused, research and development based strategy, and today we have announced further steps to drive productivity in all areas to improve returns on our investment in innovation."

Despite the cost-cutting measures announced today, it announced a 10 per cent hike in its dividend and plans to return an additional 4.5 billion US dollars (£2.9 billion) to shareholders in 2012 on top of the 9.4 billion US dollars (£6 billion) last year.

PA

Start your day with The Independent, sign up for daily news emails
ebooks
ebooksA special investigation by Andy McSmith
  • Get to the point
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

SThree: Trainee Recruitment Consultant

£20000 - £25000 per annum + OTE £45,000: SThree: SThree Group have been well e...

Ashdown Group: IT Manager / Development Manager - NW London - £58k + 15% bonus

£50000 - £667000 per annum + excellent benefits : Ashdown Group: IT Manager / ...

Recruitment Genius: Sales Consultant / Telemarketer - OTE £20,000

£13000 - £20000 per annum: Recruitment Genius: Scotland's leading life insuran...

Ashdown Group: Training Programme Manager - City, London

£40000 - £45000 per annum + benefits : Ashdown Group: Training Programme Manag...

Day In a Page

NHS struggling to monitor the safety and efficacy of its services outsourced to private providers

Who's monitoring the outsourced NHS services?

A report finds that private firms are not being properly assessed for their quality of care
Zac Goldsmith: 'I'll trigger a by-election over Heathrow'

Zac Goldsmith: 'I'll trigger a by-election over Heathrow'

The Tory MP said he did not want to stand again unless his party's manifesto ruled out a third runway. But he's doing so. Watch this space
How do Greek voters feel about Syriza's backtracking on its anti-austerity pledge?

How do Greeks feel about Syriza?

Five voters from different backgrounds tell us what they expect from Syriza's charismatic leader Alexis Tsipras
From Iraq to Libya and Syria: The wars that come back to haunt us

The wars that come back to haunt us

David Cameron should not escape blame for his role in conflicts that are still raging, argues Patrick Cockburn
Sam Baker and Lauren Laverne: Too busy to surf? Head to The Pool

Too busy to surf? Head to The Pool

A new website is trying to declutter the internet to help busy women. Holly Williams meets the founders
Heston Blumenthal to cook up a spice odyssey for British astronaut manning the International Space Station

UK's Major Tum to blast off on a spice odyssey

Nothing but the best for British astronaut as chef Heston Blumenthal cooks up his rations
John Harrison's 'longitude' clock sets new record - 300 years on

‘Longitude’ clock sets new record - 300 years on

Greenwich horologists celebrate as it keeps to within a second of real time over a 100-day test
Fears in the US of being outgunned in the vital propaganda wars by Russia, China - and even Isis - have prompted a rethink on overseas broadcasters

Let the propaganda wars begin - again

'Accurate, objective, comprehensive': that was Voice of America's creed, but now its masters want it to promote US policy, reports Rupert Cornwell
Why Japan's incredible long-distance runners will never win the London Marathon

Japan's incredible long-distance runners

Every year, Japanese long-distance runners post some of the world's fastest times – yet, come next weekend, not a single elite competitor from the country will be at the London Marathon
Why does Tom Drury remain the greatest writer you've never heard of?

Tom Drury: The quiet American

His debut was considered one of the finest novels of the past 50 years, and he is every bit the equal of his contemporaries, Jonathan Franzen, Dave Eggers and David Foster Wallace
You should judge a person by how they peel a potato

You should judge a person by how they peel a potato

Dave Hax's domestic tips are reminiscent of George Orwell's tea routine. The world might need revolution, but we like to sweat the small stuff, says DJ Taylor
Beige is back: The drab car colours of the 1970s are proving popular again

Beige to the future

Flares and flounce are back on catwalks but a revival in ’70s car paintjobs was a stack-heeled step too far – until now
Bill Granger recipes: Our chef's dishes highlight the delicate essence of fresh cheeses

Bill Granger cooks with fresh cheeses

More delicate on the palate, milder, fresh cheeses can also be kinder to the waistline
Aston Villa vs Liverpool: 'This FA Cup run has been wonderful,' says veteran Shay Given

Shay Given: 'This FA Cup run has been wonderful'

The Villa keeper has been overlooked for a long time and has unhappy memories of the national stadium – but he is savouring his chance to play at Wembley
Timeless drama of Championship race in league of its own - Michael Calvin

Michael Calvin's Last Word

Timeless drama of Championship race in league of its own